ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
Sucampo Pharmaceuticals
18.00
+0.0000
成交量:
- -
成交额:
- -
市值:
8.39亿
市盈率:
-5.47
高:
18.00
开:
18.00
低:
18.00
收:
18.00
数据加载中...
总览
公司
新闻
公告
公司资料
公司名字:
Sucampo Pharmaceuticals
交易所:
NASDAQ
成立时间:
- -
员工人数:
- -
公司地址:
- -
官网:
http://www.sucampo.com
邮编:
- -
电话:
- -
传真:
- -
简介:
Sucampo Pharmaceuticals, Inc.是根据美国特拉华州法律注册成立于1996年12月。该公司是一家国际制药公司专注于基于前列酮的专利药物的发现,开发和商业化。前列酮是一类脂肪酸化合物,在人体内自然产生的由类花生酸类物质的15-羟基前列腺素脱氢酶(15-PGDH)的酶催化的结果,如前列腺素和其他类二十二烷酸分子与15位酮基特异性合成。在两种性别的成年人,AMITIZA(鲁比前列酮)被批准用于循环免疫复合物的处理,而对于便秘的治疗,适应人群是女性年龄在18岁以上。该公司目前正在开发AMITIZA来治疗阿片样物质引起的便秘或阿片样物质引起的肠胃功能障碍。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/SCMP/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCMP\",,,,,undefined,":{"symbol":"SCMP","market":"US","secType":"STK","nameCN":"Sucampo Pharmaceuticals","latestPrice":18,"timestamp":1557518400000,"preClose":18,"halted":4,"volume":0,"delay":0,"floatShares":24340000,"shares":46637000,"eps":-3.29,"marketStatus":"退市","change":0,"latestTime":"04-28 08:52:09 EDT","open":18,"high":18,"low":18,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.29,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1186027200000,"exchange":"NASDAQ","adjPreClose":18,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCMP\",,,,,undefined,":{"symbol":"SCMP","floatShares":24340000,"roa":"--","roe":"--","lyrEps":0,"shares":46637000,"dividePrice":0,"high":18,"amplitude":0,"preClose":18,"low":18,"week52Low":9.3,"pbRate":"21.18","week52High":18.75,"institutionHeld":0,"latestPrice":18,"eps":-3.29,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.29,"open":18},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.sucampo.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.046},{"period":"1month","weight":-0.0316},{"period":"3month","weight":-0.0943},{"period":"6month","weight":-0.049},{"period":"1year","weight":0.0936},{"period":"ytd","weight":-0.0605}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sucampo Pharmaceuticals, Inc.是根据美国特拉华州法律注册成立于1996年12月。该公司是一家国际制药公司专注于基于前列酮的专利药物的发现,开发和商业化。前列酮是一类脂肪酸化合物,在人体内自然产生的由类花生酸类物质的15-羟基前列腺素脱氢酶(15-PGDH)的酶催化的结果,如前列腺素和其他类二十二烷酸分子与15位酮基特异性合成。在两种性别的成年人,AMITIZA(鲁比前列酮)被批准用于循环免疫复合物的处理,而对于便秘的治疗,适应人群是女性年龄在18岁以上。该公司目前正在开发AMITIZA来治疗阿片样物质引起的便秘或阿片样物质引起的肠胃功能障碍。","exchange":"NASDAQ","name":"Sucampo Pharmaceuticals","nameEN":"Sucampo Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SCMP\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCMP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-01","symbol":"SCMP","fiscalQuarterEnding":"2017/09","expectedEps":0.25,"name":null,"time":"盘前","type":"earning","dateTimestamp":1509508800000,"reportTimeType":"pre","actualEps":0.27},{"market":"US","date":"2017-08-02","symbol":"SCMP","fiscalQuarterEnding":"2017/06","expectedEps":0.22,"name":null,"time":"盘前","type":"earning","dateTimestamp":1501646400000,"reportTimeType":"pre","actualEps":0.28},{"market":"US","date":"2017-05-03","symbol":"SCMP","fiscalQuarterEnding":"2017/03","expectedEps":0.26,"name":null,"time":"盘前","type":"earning","dateTimestamp":1493784000000,"reportTimeType":"pre","actualEps":0.23},{"market":"US","date":"2017-03-08","symbol":"SCMP","fiscalQuarterEnding":"2016/12","expectedEps":0.49,"name":null,"time":"盘前","type":"earning","dateTimestamp":1488949200000,"reportTimeType":"pre","actualEps":0.68},{"market":"US","date":"2016-11-09","symbol":"SCMP","fiscalQuarterEnding":"2016/09","expectedEps":0.26,"name":null,"time":"盘前","type":"earning","dateTimestamp":1478667600000,"reportTimeType":"pre","actualEps":0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCMP\",market:\"US\",delay:false,,,undefined,":{}}}